About BioSight Innovations
Our Story
A specialty clinic and research organization built on the belief that exceptional science and genuine human compassion are not in conflict — they are inseparable.
Our Purpose
Why BioSight Exists
BioSight Innovations was founded to address a gap in care: people living with Thyroid Eye Disease often navigate a fragmented, confusing healthcare landscape — moving between generalists, endocrinologists, and ophthalmologists without a clear center of gravity.
We created BioSight to be that center. A place where world-class scientific expertise, active research, and genuine patient partnership converge. Where no one is rushed, dismissed, or left without answers.
Our mission is simple: To restore function, confidence, and quality of life for people affected by Thyroid Eye Disease through integrated, ethical, and research-driven care.
"Specialized Care.
Human Understanding."
This is the soul of BioSight Innovations. Every interaction — clinical, research, digital, or personal — reflects these values.
Our Commitments
-
Specialization over generalization
-
Evidence over hype
-
Compassion over speed
-
Ethics over marketing claims
-
Patient partnership over provider dominance
Locations
West Hills
7320 Woodlake Ave Suite 190 West Hills, CA 91307
Beverly Hills
9675 Brighton Way #410, Beverly Hills, CA 90210
Our Locations
Jamie Lane
Position / Role
Alex Smith
Position / Role
Charlie McMann
Position / Role
Max Johnson
Position / Role
Founder & Chief Executive Officer
Dr. Shoaib (Shoeab) Ugradar
MD MRCP (UK) BSc (Hons) · Oculoplastic Surgeon · Researcher · Innovator
A Life in Medicine & Discovery
Dr. Shoaib Ugradar is one of the world's leading oculoplastic surgeons, combining elite clinical training with a pioneering commitment to research and patient-centered care. Born and educated in London, he earned his medical degree from the University of London and a First Class Honours degree in Human Biosciences — then pursued one of only three nationally available posts in Academic Surgery in the UK, signaling from early in his career a determination to advance the field, not merely practice within it.
After completing internal medicine training and earning his MRCP (Membership of the Royal College of Physicians), Dr. Ugradar pursued subspecialty training in oculoplastic surgery across some of the UK's most prestigious institutions — including Moorfields Eye Hospital, Chelsea and Westminster Hospital, and Whipps Cross University Hospital — training under internationally recognized surgeons before being recruited to UCLA.
A Leader at UCLA
Dr. Ugradar joined the Jules Stein Eye Institute at UCLA in 2017 as an Oculoplastics Research Fellow, recruited specifically to expand the department's research footprint. He was appointed as an Attending Physician in 2019, seeing patients across UCLA Westwood, UCLA Calabasas, and UCLA Santa Monica.
Since joining UCLA, he has authored over 56 peer-reviewed publications, secured a US patent, and has two further patents pending. He received the ASOPRS Award for Excellence in Research in 2020 — the most prestigious prize in oculoplastic surgery research, awarded to only one recipient internationally per year — and secured $500,000 in private research funding.
Pioneering Research
Dr. Ugradar's research spans groundbreaking clinical studies and original device innovation. His work on teprotumumab has expanded treatment options for patients with chronic, asymmetric, and non-inflammatory Thyroid Eye Disease — populations that were previously underserved. His engineering approach to medicine has also produced two major innovations:
Credentials & Affiliations
-
Attending Physician, Oculoplastics, UCLA
-
CEO, The Orbital Radiology Center (TORC)
-
MBBS, University of London
-
BSc (First Class Honours), Human Biosciences
-
MRCP, Royal College of Physicians, UK
-
Ophthalmology Resident, Moorfields Eye Hospital
-
Oculoplastics Research Fellow, UCLA
-
GMC No: 7016530
-
CA License: SPI579
Awards & Honours
ASOPRS Excellence in Research 2020
Ophthalmology Research Gold Medal, UK 2015
Ranked #1, UK National Ophthalmology Recruitment
Young European Researcher Award 2012
Draper's Company Prize 2007
Westfield Trust Prize 2007
Freeman of London
Novel Device
The Orbiculometer
The world's first device for measuring eyelid muscle strength — opening new possibilities for diagnosing and monitoring conditions affecting the eye and periorbital muscles. US Patent No. 206030-0152-P1-US.608080.
His neuroscience background — including research at the Institute of Neurology, Queen Square on Frontotemporal Dementia and multiple sclerosis remyelination — gives Dr. Ugradar an unusually broad scientific perspective that informs his approach to every patient encounter.
Compassion as a Clinical Standard
What distinguishes Dr. Ugradar is not only his scientific accomplishment, but his unwavering commitment to treating patients as whole people. Having trained across internal medicine, neurology, and surgery, he brings an unusually holistic perspective to ophthalmic care — one that recognizes that Thyroid Eye Disease affects how patients feel, how they see themselves, and how they move through the world.
He founded BioSight Innovations on the belief that the best science and the most compassionate care are not competing goals — they are the same goal, pursued together.
Selected Publications
Over 56 peer-reviewed publications. A selection of key works in Thyroid Eye Disease and oculoplastic surgery:
-
Ugradar S, Wang Y, Douglas R. Teprotumumab for the Treatment of Asymmetric Thyroid Eye Disease. Ophthalmology, 2021.
-
Ugradar S, Wang Y, Braun J, et al. Teprotumumab for Thyroid Eye Disease: Early Response Is Not Required for Benefit. Eye, 2021.
-
Ugradar S, Wang Y, Mester T, et al. Improvement of Asymmetric Thyroid Eye Disease with Teprotumumab. British Journal of Ophthalmology, 2021.
-
Ugradar S, Manoukian N, et al. Orbital Aging: A CT-Based Study of 240 Orbits. Plastic & Reconstructive Surgery, 2021.
-
Gawargious B, Le A, Ugradar S, Demer J. Differential Regional Stiffening of Sclera by Collagen Cross-Linking. IOVS, 2019.
-
Ugradar S, Lambros V. Orbital Volume Increases with Age: A CT-Based Volumetric Study. Annals of Plastic Surgery, 2019.
Collagen Cross-Linking
Scleral & Skin Stiffening
A novel laser device that uses specific wavelengths and Riboflavin to cross-link collagen — achieving a 4× increase in scleral stiffness. Applications include myopia-related blindness prevention, floppy eyelid syndrome, and anti-aging skin treatment.
